New drug combo aims to improve colorectal cancer treatment
NCT ID NCT07150403
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether a new drug called fruquintinib, combined with standard chemotherapy, can control advanced colorectal cancer better than the current standard treatment (bevacizumab plus chemotherapy). About 74 adults whose cancer has worsened after first-line therapy will be randomly assigned to one of the two combinations. The main goal is to see how many patients have their disease controlled at 4 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fruquintinib
What this could lead to
If successful, this could provide a new second-line treatment option for people with metastatic colorectal cancer.
What could go wrong
This is an early phase 2 trial with only 74 participants, so results may not apply to everyone. The drug may not work better than the current standard or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CARCINOMA (MCRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BERGONIÉ
Bordeaux, France
Contact Email: •••••@•••••
-
BRABOIS
Vandœuvre-lès-Nancy, France
Contact Email: •••••@•••••
-
Bayeux Ch
Bayeux, France
Contact Email: •••••@•••••
-
Beauvais Ch
Beauvais, France
Contact Email: •••••@•••••
-
CHD Vendée
La Roche-sur-Yon, France
Contact Email: •••••@•••••
-
Centre Leonard de Vinci
Dechy, France
Contact Email: •••••@•••••
-
Centre Pierre Curie
Beuvry, France
Contact Email: •••••@•••••
-
Centre de Cancérologie du Grand Montpellier
Montpellier, France
Contact Email: •••••@•••••
-
Ch Nord Ouest
Villefranche-sur-Saône, France
Contact Email: •••••@•••••
-
Chauny Ch
Chauny, France
Contact Email: •••••@•••••
-
Cholet Ch
Cholet, France
Contact Email: •••••@•••••
-
Clinique Mutualiste de L'Estuaire
Saint-Nazaire, France
Contact Email: •••••@•••••
-
Clinique de Flandre
Coudekerque-Branche, France
Contact Email: •••••@•••••
-
Confluent Sas
Nantes, France
Contact Email: •••••@•••••
-
Cote Basque
Bayonne, France
Contact Email: •••••@•••••
-
Dijon Bourgogne
Dijon, France
Contact Email: •••••@•••••
-
Docteur Schaffner
Lens, France
Contact Email: •••••@•••••
-
Franco Britannique
Levallois-Perret, France
Contact Email: •••••@•••••
-
GHPSO Site de Creil
Creil, France
Contact Email: •••••@•••••
-
Ght Unyon Auxerre
Auxerre, France
Contact Email: •••••@•••••
-
Groupe Hospitalier Diaconesses Croix Saint Simon
Paris, France
Contact Email: •••••@•••••
-
Gustave Roussy
Villejuif, France
Contact Email: •••••@•••••
-
Hopital Nord Chu Saint Etienne
Saint-Priest-en-Jarez, France
Contact Email: •••••@•••••
-
Hôpital Européen G Pompidou
Paris, France
Contact Email: •••••@•••••
-
ICAN Institut de Cancérologie de Strasbourg Europe
Strasbourg, France
Contact Email: •••••@•••••
-
ICO Site Paul Papin
Angers, France
Contact Email: •••••@•••••
-
ICO Site René Gauducheau
Saint-Herblain, France
Contact Email: •••••@•••••
-
Institut de cancérologie de Bourgogne GRReCC
Dijon, France
Contact Email: •••••@•••••
-
Jean Godinot
Reims, France
Contact Email: •••••@•••••
-
Jean Mermoz
Lyon, France
Contact Email: •••••@•••••
-
Jean Minjoz
Besançon, France
Contact Email: •••••@•••••
-
LAYNÉ CH
Mont-de-Marsan, France
Contact Email: •••••@•••••
-
LEMAN
Thonon-les-Bains, France
Contact Email: •••••@•••••
-
La Miletrie
Poitiers, France
Contact Email: •••••@•••••
-
La Pitié Salpêtrière
Paris, France
Contact Email: •••••@•••••
-
La Timone
Marseille, France
Contact Email: •••••@•••••
-
Les Bonnettes
Arras, France
Contact Email: •••••@•••••
-
Robert Debré
Reims, France
Contact Email: •••••@•••••
-
Saint Côme
Compiègne, France
Contact Email: •••••@•••••
-
Saint Gregoire Chp
Saint-Grégoire, France
Contact Email: •••••@•••••
-
Saint Louis
Paris, France
Contact Email: •••••@•••••
-
Saint Malo Ch
St-Malo, France
Contact Email: •••••@•••••
-
Sainte Anne
Strasbourg, France
Contact Email: •••••@•••••
-
TIVOLI
Bordeaux, France
Contact Email: •••••@•••••
-
Valence Ch
Valence, France
Contact Email: •••••@•••••